A Double-blind, Placebo-Controlled Fixed-Dose Study of Vilazodone in Patients With Generalised Anxiety Disorder.

Trial Profile

A Double-blind, Placebo-Controlled Fixed-Dose Study of Vilazodone in Patients With Generalised Anxiety Disorder.

Completed
Phase of Trial: Phase III

Latest Information Update: 24 May 2017

At a glance

  • Drugs Vilazodone (Primary)
  • Indications Generalised anxiety disorder
  • Focus Therapeutic Use
  • Sponsors Forest Laboratories
  • Most Recent Events

    • 06 Mar 2014 According to ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
    • 15 Nov 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 26 Jul 2012 Actual initiation date (June 2012) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top